N4 Pharma Plc
N4P.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.30 | 0.09 | 0.46 |
| FCF Yield | -54.36% | -58.56% | -24.02% | -21.99% |
| EV / EBITDA | -0.95 | -0.78 | -1.28 | -3.40 |
| Quality | ||||
| ROIC | -171.94% | -106.98% | -49.28% | -72.55% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.95 | 0.80 | 1.15 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 19.65% | -45.98% | 53.26% | -28.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.51 | 0.77 | 1.61 | 0.97 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 6,749.99 | 32,973.72 | 0.00 | 0.00 |